http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20090027241-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9c55cbd632f124625c19c848aaffd9c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2007-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c6204f9f0b6b6843ec026df50d80260 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fcd759605910a9ec1a1171ac49d81ea |
| publicationDate | 2009-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20090027241-A |
| titleOfInvention | Compositions and Methods for Inhibiting Growth of SMAAD4-Deficient Cancers |
| abstract | The present invention relates to the fields of cell biology, immunology and oncology. The present invention particularly relates to the expression levels of the tumor suppressor genes smad4 (also known as dpc4 ) and integrin α ν β 6 and α ν β 6 − in cancer cells derived from a population of patients, more particularly on carcinomas such as pancreatic carcinoma. It relates to the discovery that there is a relationship between the reactivity of the population of patients with active compounds and compositions (eg, antibodies and other ligands that bind α ν β 6 ). Accordingly, the present invention is the α ν β 6 by examining the expression of the α ν β 6 and smad4 by tumor cells as a method of measuring the reactivity of the (cells from, especially, pancreatic cancer) tumor cells for the active compounds and compositions But, in particular, in ligands, including antibodies and small molecule drugs, which bind to integrin α ν β 6 on the tumor cell surface and / or block one or more components of the TGF-β pathway, especially in smad4 -deficient tumor cells. Provided are methods for treating / preventing tumor progression. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101239320-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022146025-A1 |
| priorityDate | 2006-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 955.